Collaborations
The mutual interest of progressing the highly unmet medical need of brain drug delivery keeps bringing pharma partners and to-BBB together. By combining the partner’s compounds with to-BBB’s technologies, a broad array of diseases can be addressed; amongst them: Alzheimer’s disease, pain, stroke and lysosomal storage diseases.
Such a strategic alliance between to-BBB and NeuroVive has been rewarded with a Eurostars grant of €1 million for the joint development of therapies for stroke and other acute neurological conditions.
The benefits that to-BBB’s G-Technology® offers are:
- safest available brain drug delivery platform technology;
- supporting acute and chronic therapy approaches;
- proof of concept in several animal models;
- solid patent life for any “compound-disease-combination”.
For exploring the potential of a collaboration based on your compounds, please contact Business Development. Our current and past collaborations are shown below; hover over the logos for more information.
.png){kind=small}
.png){kind=small}
.png){kind=small}